On May 16, 2019 TG Therapeutics, Inc. (NASDAQ: TGTX), reported the schedule of upcoming data presentations at the 55thAmerican Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) annual meeting, to be held May 31 – June 4, 2019, in Chicago, Illinois; the 24thEuropean Hematology Association (EHA) (Free EHA Whitepaper) annual congress, to be held June 13 – 16, 2019, in Amsterdam, Netherlands; and at the 15thInternational Conference on Malignant Lymphoma (ICML), to be held June 18 – 22, 2019, in Lugano, Switzerland (Press release, TG Therapeutics, MAY 16, 2019, View Source [SID1234536432]). Details of the data presentations are outlined below. 2290083
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Data to be presented at the ASCO (Free ASCO Whitepaper) meeting:
• Oral Presentation: Umbralisib monotherapy demonstrates efficacy and safety in patients with relapsed/refractory marginal zone lymphoma: A multicenter, open label, registration directed phase II study
Abstract Number: 7506
Session Date & Time: Tuesday, June 4, 20199:45 AM – 12:45 PM CT
– Presentation Time: 11:45AM CT
Session Title: Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
Location: McCormick Place, Room E451
Lead Author: Nathan Hale Fowler, MD, The University of Texas MD Anderson Cancer Center, Department of Lymphoma/Myeloma
The above abstract is now available via the ASCO (Free ASCO Whitepaper) meeting website at www.asco.org.
Data to be presented at the EHA (Free EHA Whitepaper) meeting:
• Poster Presentation: The novel bispecific CD47-CD19 antibody TG-1801 potentiates the activity of ublituximab-umbralisib (U2) drug combination in preclinical models of B-NHL
Session Date & Time: Saturday, June 15, 2019 17:30 – 19:00 CEST
Session Title: Lymphoma Biology & Translational Research
Location: Amsterdam RAI, Poster Session
Lead Author: Marcelo Lima Ribeiro, Vall d’Hebron University Hospital, Vall d’Hebron Institute of Oncology (VHIO), Autonomous University of Barcelona, Barcelona, Spain
The above abstract will be available today, May 16, 2019 via the EHA (Free EHA Whitepaper) meeting website at www.ehaweb.org.
Data to be presented at the ICML meeting:
• Oral Presentation: A Phase 2 Study to Assess the Safety and Efficacy of Umbralisib in Patients with Chronic Lymphocytic Leukemia (CLL) Who Are Intolerant to Prior BTK or PI3K Delta Inhibitor Therapy
Session Date & Time: Thursday, June 20, 2019 13:45 – 15:15 CEST
– Presentation Time: 15:00 CEST
Session Title: Session 3 – CLL
Location: Palazzo dei Congressi, Room A – Main Hall
Lead Author: Anthony R. Mato, MD, Memorial Sloan Kettering Cancer Center
• Oral Presentation: Phase I/II Study of Umbralisib (TGR-1202) in Combination with Ublituximab (TG-1101) and Pembrolizumab in Patients with Rel/Ref CLL and Richter’s Transformation
Session Date & Time: Thursday, June 20, 2019 17:05 – 18:05 CEST
– Presentation Time: 17:05 CEST
Session Title: Focus on Non-Clinical and Early Clinical Data with New Combinations
Location: Palazzo dei Congressi, Cinema Corso
Lead Author: Anthony R. Mato, MD, Memorial Sloan Kettering Cancer Center
• Oral Presentation: Umbralisib Monotherapy Demonstrates Efficacy and Safety in Patients with Relapsed/Refractory Marginal Zone Lymphoma: A Multicenter, Open-Label, Registration Directed Phase 2 Study
Session Date & Time: Saturday, June 22, 2019 10:15 – 11:15 CEST
– Presentation Time: 10:45 CEST
Session Title: Focus on Indolent Non-Follicular Lymphoma
Location: Palazzo dei Congressi, Room A and B
Lead Author: Pierre-Luigi Zinzani, MD, University of Bologna, Institute of Hematology "L. e A. Seràgnoli"
• Poster Presentation: The novel bispecific CD47-CD19 antibody TG-1801 potentiates the activity of ublituximab-umbralisib (U2) drug combination in preclinical models of B-NHL
Session Date & Time: Wednesday, June 19 (12:00-17:00 CEST), Thursday, 20 (9:00-17:00 CEST) and Friday, June 21 (9:00-18:30 CEST)
Location: Palazzo dei Congressi, Marquee Parco Ciani
Lead Author: Marcelo Lima Ribeiro, Vall d’Hebron University Hospital, Vall d’Hebron Institute of Oncology (VHIO), Autonomous University of Barcelona, Barcelona, Spain
The above abstracts will be available via the ICML meeting website at www.lymphcon.ch on June 12, 2019.
Following each presentation, the data presented will be available on the Publications page, located within the Pipeline section, of the Company’s website at www.tgtherapeutics.com/publications.cfm.